Miltefosine: a promising agent for leishmaniasis
References
Azzouz, S, Maach M, Garcia RG, Osuna A. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin Pharmacol Toxicol. 2005;96(1):60-65.
Vakil N H, Fujinami N, Shah PJ. Pharmacotherapy for Leishmaniasis in the United States: Focus on miltefosine. Pharmacotherapy. 2015;35(5):536-45.
Tuon FF, Amato V S, Graf ME, Siqueira AM, Nicodemo AC, AmatoNeto V. Treatment of New World cutaneous leishmaniasis- a systematic review with a meta-analysis. Int J Dermatol. 2008;47:109-124.
Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Antimicrob Agents Chemother. 2012;67:2576-97.
Pinto-Martinez A K, Rodriguez-Durán J, Serrano-Martin X, Hernandez-Rodriguez V, Benaim G. Mechanism of action of miltefosine on Leishmania donovani involves the impairment of acidocalcisome function and the activation of the sphingosine-dependent plasma membrane Ca2+ channel. Antimicrob Agents Chemother. 2018;62(1):e01614-17.
David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009;22:491-502.
Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100(1):S17-S20.
Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health. 2001;6(2):928-34.
Fischer C, Voss A, Engel J. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Med Microbiol Immunol. 2001;190(1-2):85-7.
Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998;352(9143):1821-3.
Rubiano LC, Miranda MC, Muvdi A, Montero LM, Rodríguez-Barraquer I, Garcerant D et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis. 2012;205:684-92.